Abstract
E. Senkus1, S. Kyriakides2, F. Penault-Llorca3,4, P. Poortmans5, A. Thompson6, S. Zackrisson7 & F. Cardoso8,9, on behalf of the ESMO Guidelines Working Group* Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; Europa Donna Cyprus, Nicosia, Cyprus; Department of Pathology, Centre Jean Perrin, Clermont-Ferrand; EA 4677 Universite d’Auvergne, Clermont-Ferrand, France; Institute Verbeeten, Tilburg, The Netherlands; Dundee Cancer Centre, University of Dundee, Dundee, UK; Diagnostic Radiology, Lund University, Malmo, Sweden; European School of Oncology, Milan, Italy; Breast Cancer Unit, Champalimaud Centre Center, Lisbon, Portugal
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
